Purpura After Two New Prescriptions: Waiting Out a Culprit That Won’t Name Itself
Cutaneous vasculitis usually resolves once the offending drug is gone — but with two candidate drugs and lesions still appearing after both were stopped, “just wait” is no longer an uncontested plan.
A cluster of small, non-blanching red-purple spots appeared on both of Nadia F.'s shins four days after the second of two new drugs entered her system in close succession — trimethoprim-sulfamethoxazole, started nine days ago for a sinus infection, and lamotrigine, a new anticonvulsant her neurologist had been titrating toward for months for a seizure disorder, added six days ago. Nadia, a 41-year-old dental hygienist, watched the spots spread over the next two days to her thighs, and by the time she came in they numbered well over sixty individually countable lesions — palpable, tender, and unmistakably purpuric rather than a simple rash.
A punch biopsy of one lesion confirmed leukocytoclastic vasculitis with immune complex deposition on direct immunofluorescence; ANCA, complement levels, and a basic metabolic panel were all normal, and a same-day urinalysis showed no hematuria or proteinuria — real, reassuring evidence that this is skin-limited disease without renal involvement, not merely an assumption made because she feels otherwise well. Both suspect drugs were stopped forty-eight hours ago. New lesions have continued to appear since then, several on her thighs, and two of the largest on her left shin have developed a small area of central dusky discoloration that has not yet progressed to frank ulceration but has the team watching it closely.
Trimethoprim-sulfamethoxazole and lamotrigine have genuinely different elimination profiles — the sulfa combination clears within roughly a day and a half in someone with normal renal function, while lamotrigine's half-life, even without an enzyme-inducing interaction to shorten it, runs closer to a full day and can take several days to fall to a level low enough that new immune-complex formation would be expected to stop. Two days off both drugs is therefore not two days of clearance for each. On the sulfa she is roughly five half-lives out and past the point where new immune-complex formation should still be driven by it; on the lamotrigine she is barely two, and squarely inside the window where it would be. The lesions that appeared this morning are evidence about one of these drugs and almost none about the other, which is not how they are being counted at the bedside.
Reading a lesion count that hasn’t stopped climbing
The biopsy and labs are exactly the reassuring picture we'd want — skin-limited, no renal involvement, no systemic vasculitis. The overwhelming majority of drug-induced cutaneous vasculitis resolves on its own within a few weeks once the culprit is withdrawn. Both suspect drugs are already stopped. I'd manage this with leg elevation, NSAIDs for discomfort, and close follow-up rather than start systemic steroids for a condition this likely to resolve on its own.
I agree with the natural history in general, but I'm watching those two lesions on her shin more closely than that framing accounts for. Central dusky discoloration is an early sign of tissue compromise, and if that progresses to frank ulceration she's looking at real scarring — a permanent cost from a condition we're calling self-limited.
'Likely to resolve on its own' is a population statement. My concern is specifically about the lesions already trending the wrong way in front of us, not the average case.
I think you're both reading the same fact — new lesions at 48 hours — and drawing different conclusions because neither of you has separated the two drugs' actual clearance times. TMP-SMX is essentially gone from her system by now. Lamotrigine is not; at her dose, meaningful drug level can persist for several more days even without an inducer shortening it.
That means new lesions right now don't yet tell us the culprit has failed to clear — if lamotrigine is the actual cause, we're still inside its expected window. I'd hold steroids for now and re-examine her in 48 more hours, once lamotrigine has genuinely cleared. If lesions are still forming after that, the Rheumatologist's concern about the necrotic changes becomes the stronger argument, and I'd support starting a taper then.
Systemic steroids were held, and a repeat exam was scheduled for 48 hours later — timed specifically to fall after lamotrigine's expected clearance, per the Clinical Pharmacologist's proposed trigger, rather than at an arbitrary follow-up interval.
Not agreed in advance: what counts as 'still appearing' at that recheck. The Dermatologist would accept one or two new lesions as within the tail of a resolving process; the Rheumatologist, given the existing necrotic change, wants any new lesion at all — or any progression of the two already concerning ones — to trigger the steroid taper immediately rather than allow a second waiting interval. Both agreed to examine her together at that visit rather than have either position decide alone.